lucatumumab (CHIR 12.12) / Novartis, Ligand - LARVOL DELTA

Combined Cryoablation, Lucan-Sartuzumab, and Immunotherapy for Advanced Cholangiocarcinoma (SPICE Trial): A Phase II Single-Arm Study (ChiCTR) - P2 | N=25 | Sponsor: Lishui Central Hospital; Lishui Central Hospital

New P2 trial • Biliary Cancer • Cholangiocarcinoma • Oncology • Solid Tumor

A Single-Arm, Multicenter, Phase II Clinical Study of Lucosacituzumab in Combination with Immune Checkpoint Inhibitors as Maintenance Therapy for Patients with Extensive-Stage Small Cell Lung Cancer Without Progression After Induction Therapy (ChiCTR) - P2 | N=31 | Not yet recruiting | Sponsor: Sichuan Cancer Hospital; Sichuan Cancer Hospital

New P2 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Aberrant expression of β5t in the periphery induces a self-reactive T-cell response (IMMUNOLOGY 2020) - "In β5i-/-β5t-Tg mice, the percentage of naïve　CD44lowCD122low was reduced, and the percentage of memory CD44highCD122high CD8+ T cells was significantly elevated. These results demonstrate that the aberrant peripheral expression of β5t disrupts the maintenance of a naïve pool of CD8+ T cells and induces autoreactive T-cell responses. The self-peptides generated by β5t are required to confine in the thymus to avoid autoimmunity in the peripheral tissues, and self-peptides mimicking β5t-producing peptides in the periphery may cause the failure of immunological regulation and tolerance."

IO Biomarker • CD44 • CD8 • PD-1

Emerging immune targets for the treatment of multiple myeloma. (PubMed, Immunotherapy) - "...Other monoclonal antibodies that have shown efficacy in combination therapy include siltuximab (OR: 66%), indatuximab (OR: 78%), isatuximab (OR: 64.5%), pembrolizumab (OR: 60%), bevacizumab (OR: 70%), dacetuzumab (OR: 39%) and lorvotuzumab (OR: 56.4%). No OR was observed with monotherapy using BI-505, siltuximab, bevacizumab, AVE-1642, figitumumab, atacicept, milatuzumab, dacetuzumab, lucatumumab, IPH2101, lorvotuzumab, BT062 and nivolumab...A recent experience of CAR T-cell (B-cell maturation antigen) therapy in advanced MM has shown global response of 100%. The future of monoclonal antibodies and adoptive T cells for MM treatment seems promising."

Journal